PWAM
CORT icon

Private Wealth Asset Management’s Corcept Therapeutics CORT Stock Holding History

Private Wealth Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$209 – 974
2025
Q4 		$209 Hold
6
– – ﹤0.01% 992
2025
Q3 		$499 Hold
6
– – ﹤0.01% 882
2025
Q2 		$440 Sell
6
-26
-81% -$1.89K ﹤0.01% 880
2025
Q1 		$3.65K Buy
+32
New +$1.95K ﹤0.01% 758

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Private Wealth Asset Management's CORT Position: Q1 2026 in Review

Private Wealth Asset Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 6 shares — an estimated $209 sold.

Private Wealth Asset Management first reported a position in CORT in Q1 2025 and held it in 4 quarters. The position peaked at $3.65K in Q1 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Private Wealth Asset Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Private Wealth Asset Management sold 6 Corcept Therapeutics shares in Q1 2026, an estimated $209.
  • Private Wealth Asset Management first reported a position in Corcept Therapeutics in Q1 2025 and held it in 4 quarters.
  • Private Wealth Asset Management's Corcept Therapeutics position peaked at $3.65K in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Private Wealth Asset Management's 13F filing for Q1 2026, filed 6 May 2026.